Nunes: The Russian Collusion Hoax Meets An Unbelievable

New Post Public Reply Private Reply Replies (0) Message Board
Lmcat
226
Nunes: The Russian Collusion Hoax Meets An Unbelievable End
Fri, 04/05/2019



As the Russia collusion hoax hurtles toward its demise, it’s important to consider how this destructive information operation rampaged through vital American institutions for more than two years, and what can be done to stop such a damaging episode from recurring.



While the hoax was fueled by a wide array of false accusations, misleading leaks of ostensibly classified information, and bad-faith investigative actions by government officials, one vital element was indispensable to the overall operation: the Steele dossier.









These allegations, which relied heavily on Russian sources cultivated by Christopher Steele, were spoon-fed to Trump opponents in the U.S. government, including officials in law enforcement and intelligence.

FBI-DOJ-Cartoon-Trump-620x487.jpg

The efforts to feed the dossier’s allegations into top levels of the U.S. government, particularly intelligence agencies, were championed by Steele, Fusion GPS co-founder Glenn Simpson, and various intermediaries. These allegations were given directly to the FBI and Justice Department, while similar allegations were fed into the State Department by long-time Clinton aide Sidney Blumenthal.

Their efforts were remarkably effective. Officials within the FBI and DOJ, whether knowingly or unintentionally, provided essential support to the hoax conspirators, bypassing normal procedures and steering the information away from those who would view it critically. The dossier soon metastasized within the government, was cloaked in secrecy, and evaded serious scrutiny.



High-ranking officials such as then-FBI general counsel James Baker and then-Associate Deputy Attorney General Bruce Ohr were among those whose actions advanced the hoax. Ohr, one of the most senior officials within the DOJ, took the unprecedented step of providing to Steele a back door into the FBI investigation.

This enabled the former British spy to continue to feed information to investigators, even though he had been terminated by the FBI for leaking to the press and was no longer a valid source. Even worse, Ohr directly briefed Andrew Weissmann and Zainab Ahmad, two DOJ officials who were later assigned to special counsel Robert Mueller's investigation. In short, the investigation was marked by glaring irregularities that would normally be deemed intolerable.

According to Ohr’s congressional testimony, he told top-level FBI officials as early as August or September 2016 that Steele was biased against Trump, that Steele’s work was connected to the Clinton campaign, and that Steele's material was of questionable reliability. Steele himself confirmed that last point in a British court case in which he acknowledged his allegations included unverified information.
Yet even after this revelation, intelligence leaders continued to cite the Steele dossier in applications to renew the Foreign Intelligence Surveillance Act warrant on former Trump campaign adviser Carter Page.

It is astonishing that intelligence leaders did not immediately recognize they were being manipulated in an information operation or understand the danger that the dossier could contain deliberate disinformation from Steele’s Russian sources.



In fact, it is impossible to believe in light of everything we now know about the FBI’s conduct of this investigation, including the astounding level of anti-Trump animus shown by high-level FBI figures like Peter Strzok and Lisa Page, as well as the inspector general’s discovery of a shocking number of leaks by FBI officials.



It’s now clear that top intelligence officials were perfectly well aware of the dubiousness of the dossier, but they embraced it anyway because it justified actions they wanted to take - turning the full force of our intelligence agencies first against a political candidate and then against a sitting president.



The hoax itself was a gift to our nation’s adversaries, most notably Russia.
The abuse of intelligence for political purposes is insidious in any democracy. It undermines trust in democratic institutions, and it damages the reputation of the brave men and women who are working to keep us safe. This unethical conduct has had major repercussions on America’s body politic, creating a yearslong political crisis whose full effects remain to be seen.

Having extensively investigated this abuse, House Intelligence Committee Republicans will soon be submitting criminal referrals on numerous individuals involved in these matters.



These people must be held to account to prevent similar abuses from occurring in the future.

The men and women of our intelligence community perform an essential service defending American national security, and their ability to carry out their mission cannot be compromised by biased actors who seek to transform the intelligence agencies into weapons of political warfare.



https://www.zerohedge.com/news/2019-04-05/nun...vbable-end
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ivonescimab Promises New Hope for Advanced BTC Patients

Updated Category News Views 280

Shifting the Paradigm in Biliary Tract Cancer Treatment Here's the scoop from the bustling world of oncology: the trial of Ivonescimab plus chemotherapy is stirring waves among experts in advanced biliary tract cancer (BTC). Contrary to the usual drowsy mornings with coffee and market pages, this data from Hong Kong wasn't about Wall Street this time. This trial might...

Continue Reading
LexisNexis Debuts AI-Guided Field Clarity at IACP 2026

Updated Category News Views 84

LexisNexis Takes a Serious Step Forward The world of law enforcement reporting just got a shake-up. LexisNexis Coplogic Solutions launched a souped-up version of its Desk Officer Reporting System (DORS) at the IACP 2026 event. They paired DORS with Field Clarity, a newfangled AI-powered assistant that aims to make police reporting slicker and more accurate. You can bet...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 393

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
Lilly's Olomorasib: New Data Sparks Hope for G12C NSCLC

Updated Category News Views 186

New Data Unveiling Potential Shifts in NSCLC Treatment Man, if there's one thing the oncology world craved, it's progress against KRAS G12C-mutant non-small cell lung cancer (NSCLC). We're talking about a challenge as tough as a two-dollar steak. But hey, Eli Lilly's (NYSE:LLY) putting some serious cards on the table with olomorasib, and folks at the ESMO 2026 Congress...

Continue Reading
Clarins Dazzles Austin with Skin Longevity Event

Updated Category News Views 21

Clarins Takes Austin by Storm Under the vast Austin sky, something remarkable unfolded as Clarins transformed the scene with a flashy rooftop affair that screamed innovation and elegance. They weren’t just showing off fancy bottles of beauty potion; they were stirring the pot, merging science with a splash of high-end glitz. This wasn’t just another product pitch—it...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 299

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Sinclair Faces Labor Lawsuit for Break-time Violations

Updated Category News Views 175

Sinclair Television Caught in Labor Law Storm When you think of flaring tempers and boardroom brawls, you typically don't think of your everyday TV station. But right now, Sinclair Television of California, LLC is in the hot seat, accused of playing fast and loose with wage packets—specifically, allegedly denying meal periods and rest breaks that California labor laws...

Continue Reading
Johnson & Johnson's JNJ-6143 Shines in Prostate Cancer Study

Updated Category News Views 241

Prostate Cancer's Persistent Challenge No one in the healthcare game needs the reminder: prostate cancer is no walk in the park, especially for those grappling with advanced stages. Now picture this—you're on your sixth treatment, and the cloud is not lifting. It's a battle that never ends, with traditional therapies sometimes barely holding the line. JNJ-6143's New...

Continue Reading
Gildan Activewear Faces Legal Battle Over Alleged Fraud

Updated Category News Views 176

Investor Alert: Gildan's Legal Showdown Alright, here's a twist you didn't see coming—or maybe you did if you've been tracking the ticker tapes like a hawk. Gildan Activewear Inc. (NYSE:GIL) is stuck in the kind of hot water that can scald the bottom line. The Stakes: Racing Towards December 14 Marked on your calendar, December 14, is a date of some significance if...

Continue Reading
DigitalXForce Shakes Up GRC: AI-Infused X-ROC Launch

Updated Category News Views 98

Turning Risk Management on Its Head Well, here's a company not just tinkering around the edges but flipping the script on Governance, Risk, and Compliance (GRC) with their latest rollout: DigitalXForce and its X-ROC. Yeah, it's yet another acronym to juggle, but don't roll your eyes just yet. This AI-driven beast isn't about occasional boardroom reports. No sir, it's a...

Continue Reading

Top 5 Most Recently Viewed Articles

Morgan Stanley Projects Strong Upswing for Consumer Finance

Updated Category News Views 259

Morgan Stanley's Positive Outlook for Consumer Finance Stocks Morgan Stanley has recently made an uplifting adjustment to its outlook on consumer finance stocks, now branding them as "attractive." This decision stems from robust fundamentals and an improved regulatory environment, setting an optimistic tone for the sector. Key Drivers of Change The primary catalysts...

Continue Reading
Significant Board Restructuring at O2Gold Inc. Announced

Updated Category News Views 71

O2Gold Board Announces Key Changes O2Gold Inc. (NEX: OTGO.H), a dedicated mineral exploration company, has recently undergone a significant change in its board structure. The company has announced that Roger Lemaitre has resigned from his position as a director. This decision marks a pivotal moment for O2Gold as it continues to navigate its exploration initiatives....

Continue Reading
Taylor Morrison Launches Holiday Initiative to Support Homeowners

Updated Category News Views 265

Help for Homeowners During the Holidays In a time when financial strain can be prominent, especially during the holidays, Taylor Morrison (NYSE: TMHC) is stepping up to lend a hand. The renowned homebuilder has introduced an initiative designed to support homeowners facing the threat of foreclosure. With the holiday season often heightening financial challenges, the...

Continue Reading
flatexDEGIRO Moves Ahead After Ending BaFin Oversight

Updated Category News Views 188

flatexDEGIRO Ends Special Commissioner Mandate FRANKFURT - flatexDEGIRO AG, a prominent German financial services provider, has officially announced the conclusion of the special commissioner mandate set by the Federal Financial Supervisory Authority (BaFin). This change will take effect on a specified date in the future. The company has made significant strides in...

Continue Reading
Investigating Alvotech's Regulatory Challenges After Stock Drop

Updated Category News Views 125

Alvotech Faces Scrutiny over Manufacturing Issues National shareholder rights firm Hagens Berman is currently analyzing Alvotech (NASDAQ: ALVO) regarding potential misrepresentations in their disclosures tied to manufacturing operations and the regulatory status of their primary biosimilar candidate, AVT05. Impact of FDA's Complete Response Letter The investigation stems...

Continue Reading